Virax Biolabs Group Ltd (VRAX) Invested Capital (2021 - 2025)

Virax Biolabs (VRAX) has 5 years of Invested Capital data on file, last reported at $5.7 million in Q1 2025.

• In Q1 2025, Invested Capital rose 10.85% year-over-year to $5.7 million; the TTM figure through Mar 2025 stood at $5.7 million (up 10.85% YoY), while the FY2025 annual figure was $5.7 million, up 10.85% from the prior year.
• Invested Capital advanced to $5.7 million in Q1 2025, from $5.1 million in the prior quarter.
• Across five years, Invested Capital topped out at $8.9 million in Q1 2023 and bottomed at -$1.2 million in Q1 2022.
• A 5-year average of $3.5 million and a median of $5.1 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital tumbled 43.87% — and 2023, when it soared 844.04%.
• Year by year, Invested Capital stood at -$831814.0 in 2021, then tumbled by 43.87% to -$1.2 million in 2022, then soared by 844.04% to $8.9 million in 2023, then tumbled by 42.29% to $5.1 million in 2024, then rose by 10.85% to $5.7 million in 2025.
• The last three Invested Capital figures came in at $5.7 million (Q1 2025), $5.1 million (Q1 2024), and $8.9 million (Q1 2023), per Business Quant data.

Peer Comparison